Total trials
128
Active
24
Phase 3
7
Total enrollment
225,131
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Botulinum toxin type A | — | — | — | — | — | 1 | |
| Celecoxib | — | — | — | — | — | 1 | |
| Minocyclin | — | — | — | — | — | 1 | |
| Gardasil 9 | — | — | — | — | — | 1 |
Next readouts
- 2026-09
- 2026-12-30
- 2029-01-01
Top conditions
- Stroke11
- Cervical Cancer5
- Human Papilloma Virus5
- HPV-Related Cervical Carcinoma5
- Overactive Bladder5
- Cervical Intraepithelial Neoplasia4
- Epilepsy4
- Gait, Hemiplegic3
Frequently asked questions about Universiteit Antwerpen
- How many clinical trials does Universiteit Antwerpen have on ClinicalTrials.gov?
- Universiteit Antwerpen is listed as the lead sponsor on 128 clinical trials in ClinicalTrials.gov, 24 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Universiteit Antwerpen's trials are in Phase 3?
- 7 of Universiteit Antwerpen's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Universiteit Antwerpen focus on?
- Universiteit Antwerpen's most-studied conditions on ClinicalTrials.gov are Stroke, Cervical Cancer, Human Papilloma Virus, HPV-Related Cervical Carcinoma, Overactive Bladder.
- When are Universiteit Antwerpen's next clinical trial readouts?
- Universiteit Antwerpen has 3 upcoming primary-completion readouts tracked here; the soonest is “INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive Disorder”, expected around 2026-09.